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Abstract
Background—DNA damage is an established mediator of carcinogenesis, though GWAS have 
identified few significant loci. This cross-cancer site, pooled analysis was performed to increase 
the power to detect common variants of DNA repair genes associated with cancer susceptibility.
Methods—We conducted a cross-cancer analysis of 60,297 SNPs, at 229 DNA repair gene 
regions, using data from the NCI Genetic Associations and Mechanisms in Oncology (GAME-
ON) Network. Our analysis included data from 32 GWAS and 48,734 controls and 51,537 cases 
across five cancer sites (breast, colon, lung, ovary, and prostate). Because of the unavailability of 
individual data, data were analyzed at the aggregate level. Meta-analysis was performed using the 
Association analysis for SubSETs (ASSET) software. To test for genetic associations that might 
escape individual variant testing due to small effect sizes, pathway analysis of eight DNA repair 
pathways was performed using hierarchical modeling.
Results—We identified three susceptibility DNA repair genes, RAD51B (p < 5.09 × 10−6), 
MSH5 (p < 5.09 × 10−6) and BRCA2 (p = 5.70 × 10−6). Hierarchical modeling identified several 
pleiotropic associations with cancer risk in the base excision repair, nucleotide excision repair, 
mismatch repair, and homologous recombination pathways.
Conclusions—Only three susceptibility loci were identified which had all been previously 
reported. In contrast, hierarchical modeling identified several pleiotropic cancer risk associations 
in key DNA repair pathways.
Impact—Results suggest that many common variants in DNA repair genes are likely associated 
with cancer susceptibility through small effect sizes that do not meet stringent significance testing 
criteria.
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Introduction
DNA damage is an established mediator of carcinogenesis (1). Several carcinogens (e.g. 
chemical mutagens, viruses, and irradiation) are known to cause cancer through their ability 
to damage DNA (2–6). Consistent with this established model of carcinogenesis, mutations 
in many genes known to confer cancer risk (e.g. TP53 (7), ATM (8), BRCA1 (9), BRCA2 
(10)), are known to play major roles in DNA damage repair and signaling response (11–15). 
However, while mutations in these genes are associated with high degrees of individual 
cancer risk (7, 9, 10), these rare events explain only a small fraction of all cancers (5). Given 
the importance of DNA damage to carcinogenesis, it is plausible that cancer risk would be 
conferred by common variants of these and other DNA repair genes, and that this risk could 
be measured in large, genome-wide association studies (GWAS).
GWAS have identified hundreds of single nucleotide polymorphisms (SNPs) and 
susceptibility loci associated with risk for various cancers (16–26). However, few GWAS 
have identified cancer susceptibility loci near DNA repair genes at stringent levels of 
significance that have also been shown to function through altered DNA repair (21, 24, 26, 
27). These data suggest that common variants in DNA repair genes may not make important 
contributions to cancer susceptibility, and that cancer susceptibility may be mostly conferred 
by high-risk, rare variants within this class of genes. However, it is possible that 
underpowered association studies could miss common variants with weak effect sizes. In 
order to investigate this hypothesis, a comprehensive candidate gene association study of 
DNA repair genes was performed.
The present study analyzes genetic data from 229 DNA repair genes. In order to increase the 
power to detect common variant effects, a meta-analysis was performed, using the NCI 
Genetic Associations and Mechanisms in Oncology (GAME-ON) Network database, which 
includes data from breast, colon, lung, ovary, and prostate cancer. The Association analysis 
for SubSETs (ASSET) software package (Bioconductor) was used to conduct the meta-
analysis of the large dataset (48,734 controls, 51,537 cases), which also allows for the 
evaluation of subset effects in a potentially heterogeneous dataset. Since the effect for each 
SNP may only reach significance in certain cancers (a subset of studies) this represents a 
powerful and practical approach to meta-analysis. The use of a candidate gene study 
restricted to DNA repair genes, the size and comprehensiveness of the GAME-ON database, 
and the use of ASSET to interrogate this large dataset for subset effects with minimal loss of 
power, represents a significantly more powerful approach to detect individual genetic 
variants in loci near DNA repair genes than has been previously attempted.
In order to test for cancer risk associations among DNA repair genes, which might escape 
individual variant testing due to weak effect sizes, dimensional reduction of the dataset was 
also performed by pathway analysis, using hierarchical modeling (28, 29). DNA repair 
genes segregate into fairly exclusive, well-defined pathway categories, which provides a 
strong, rational basis to use this information as a means to achieve dimensional reduction of 
the dataset, as findings in the pathway categories are therefore more likely to have 
underlying biological meaning and less likely to be an artifact of pathway analysis 
procedures. The hierarchical modeling procedure was selected for use in this study because 
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of its compatibility with the summary-level data available in the GAME-ON database and 
because this approach to pathway analysis uses information from across the entire dataset, 
instead of being driven by only a handful of the most significant individual variants. Using 
pathway membership as binary covariates, the multivariate regression framework of 
hierarchical modeling allowed for estimation of pathway effect size and significance (p-
value) for each pathway. Significant effects in the pathway covariates were interpreted as 
supportive evidence for the associations between variants in the DNA repair pathways and 
cancer susceptibility.
Materials and Methods
Study Population
The GAME-ON Network (http://epi.grants.cancer.gov/gameon/) includes GWAS data from 
32 studies across North America and Europe as well as Australia, representing five common 
cancer sites: breast, colon, lung, ovary, and prostate (16, 17, 19–23, 30–33). In total, this 
included 51,537 cancer cases and 48,734 controls. Data analyzed included summary 
statistics for each study, after adjusting for age, gender, and population stratification using 
principal components as applicable (Supplementary Table 1). Genomic variant data was 
imputed to the 1000 Genomes reference panel using either MACH or IMPUTE (34–36). 
Imputation was separately carried out for each cancer site. Following imputation, there were 
6,300,179 SNPs available for analysis, which were shared among all the GAME-ON 
databases. To avoid population stratification, all study participants included in the analysis 
were of European descent. Table 1 summarizes the sample sizes of each participating study, 
and more detailed characteristics are provided in Supplementary Table 1.
Gene, SNP, and pathway selection
We initially identified 247 DNA damage repair and signaling response genes using Kyoto 
Encyclopedia of Genes and Genomes (KEGG) Pathway Database (http://www.genome.jp/
kegg/pathway.html). Since the GAME-ON data did not include sex chromosomes, the gene 
list was reduced to 229 genes for the final analysis (Supplementary Table 2).
Single nucleotide polymorphisms (SNPs) were queried from the region of every gene 
included in the study, using dbSNP (http://www.ncbi.nlm.nih.gov/snp/) and the GRCh38 
reference build of the human genome. There is no data to suggest how far a SNP may be 
from a gene and still have functional effects on that gene. It is known that variants that affect 
gene activity can be located as far as 100 kb away from the start and stop sites of the genes; 
however, the inclusion of a larger search window reduces study power and increases the 
chance that associations are found that apply to genes other than the one of interest. In an 
attempt to address these competing concerns, gene regions were a priori defined as 50 kb 
upstream and downstream of the official start and stop sites for each gene (Supplementary 
Table 2). Selection criteria for a SNP’s inclusion into the study included MAF > 0.01 and 
being part of the 1000 Genomes database. This resulted in the initial selection of 156,804 
SNPs. SNPs were then omitted from the analysis if they were not present within every 
dataset in the GAME-ON network, resulting in a final count of 60,297 SNPs to be included 
in this study (Supplementary Table 2).
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Statistical Analysis
Because of the unavailability of individual data for all five cancer sites, the data were 
analyzed at the aggregate level only. All datasets were standardized so that the reference 
allele for each SNP was the same across datasets. Summary statistics for each genetic 
variant were obtained for each cancer site and for select histologic subtypes of breast 
(estrogen receptor (ER)-negative), prostate (aggressive), ovarian (serous and mucinous) and 
lung (adenocarcinoma) cancers (Table 1). Lung adenocarcinoma, serous ovarian cancer, and 
mucinous ovarian cancer were subtypes chosen for special inclusion into this study, given 
their prior associations with DNA repair genes (24, 37, 38). ER-negative breast cancer and 
aggressive prostate cancer subsets were also included to reflect genetic associations that may 
be linked with more aggressive forms of the disease. Aggressive prostate cancer was defined 
as disease cases having a Gleason score of 8 or greater (except for the BPC3 and CGEMS 
studies which included cases with tumor stage C or greater or cases with a Gleason score of 
7 or greater, respectively) (30).
All dataset summary statistics included odds ratios (ORs) and standard errors (SEs) derived 
from logistic regression analyses. Study-specific results were combined within each cancer 
site using a fixed effects model. Pooled estimates by cancer site were adjusted for age, 
principal components for population structure, and gender, where applicable.
Using the subset-based approach provided for by the ASSET software package (http://
www.bioconductor.org) (39), each genetic variant was evaluated for pleiotropic association 
with cancer risk across multiple cancer sites and histologic subtype. For every genetic 
variant, effect sizes between studies were combined, by finding the best subset to maximize 
the test statistic. The final test statistic for each SNP is obtained by maximizing the subset-
specific test statistic over all possible subsets, correcting for multiple-testing. ASSET 
calculates the effect size and significance of each SNP across all studies and also returns a 
list of studies that constitute the “best subset” of studies associated with the SNP under the 
assumption of a common direction of association (“1-sided ASSET analysis”) or it can allow 
for the assumption that significant effects may occur in opposite directions for the same 
genetic variant, between studies (“2-sided ASSET analysis”). In practice, however, genetic 
loci that are detected as significant across cancer studies have an overwhelming tendency to 
have the same direction of association. In this report it was assumed that variants of DNA 
repair genes were not likely to have effects that were opposite in direction across cancer 
sites.
The correlation between studies was corrected for by tabulating the number of shared cases 
and controls between studies and generating a covariance matrix when estimating standard 
errors. This included overlapping controls from the UK ovarian cancer and UK breast cancer 
GWAS, both of which included controls form the Wellcome Trust Case Control Consortium 
(WTCCC). Since significance effects for each SNP may only exist in certain cancers (a 
subset of studies) this represents a powerful and practical approach to meta-analysis. Of the 
60,297 SNPs included in the study, 9,806 SNPs were found to not be in high linkage 
disequilibrium (LD) (R2 > 0.70). This SNP count was used to set the threshold for a genetic 
variant to reach statistical significance, using the Bonferroni correction, p = 5.09 × 10−6. The 
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statistical significance for each genetic variant was calculated using the Bonferroni method 
in ASSET.
Hierarchical modeling, pathway analysis
To reduce the correlation structure in the SNP dataset, SNPs were pruned from the analysis 
if they were found to be in high LD (R2 > 0.70), as determined using the online SNP 
Annotation and Proxy Search (SNAP) tool (Broad Institute, http://
www.broadinstitute.org/mpg/snap/). If LD information for a SNP was not available from the 
SNAP tool, it was pruned from the analysis. This resulted in 9,806 SNPs available for 
pathway analyses (Table 3).
SNP pathway membership was determined based on the DNA repair gene it was linked to 
and that gene’s membership in DNA damage repair and signaling pathways, as indicated by 
the KEGG Pathway Database (Supplementary Table 3). As a result, it was possible for a 
SNP to be a member of more than one pathway. The hierarchical modeling method (28, 29) 
used was performed in R (R Foundation for Statistical Computing, http://www.R-
project.org/, Version 3.1.1, 2014). Briefly, hierarchical modeling was performed using the 
summary level data from the GAME-ON consortium. First-stage estimates of SNP 
association with each cancer site (OR, SE, and p-values < 0.05), were generated by adjusting 
for principal components, as applicable. This information was then entered into a 
multivariate regression framework, incorporating higher level information about the SNP 
(i.e. pathway membership as binary covariates) in order to improve the ranking of results. 
The effect size and association for each DNA repair pathway covariate was calculated for 
each cancer site. The SEs were estimated based on the folded-normal distribution (40).
Results
Figure 1 illustrates the genomic distribution for all SNPs included in the analysis and the 
corresponding p-values for association with cancer risk across one or more cancer sites. 
Manhattan plots for each of the studies included in the meta-analysis were also generated 
(Supplemental Figure 1). After correction for multiple comparisons, 29 genomic markers 
reached statistical significance. Twenty-six of the 29 SNPs were within the RAD51B gene 
locus (14q24.1). Three of the 29 statistically significant SNPs were within the MSH5 gene 
locus (6p21.33). A single SNP, near the BRCA2 gene locus (13q13.1), reached borderline 
significance (p = 5.70 × 10−6). This SNP was at the edge of the defined gene locus window 
and was actually located within the FRY gene. While FRY has been previously associated 
with prostate cancer risk, it is not directly involved in DNA damage repair (41). The other 
168 SNPs within the BRCA2 gene did not reach significance testing criteria.
The SNPs with the lowest p-value at each locus (RAD51B, MSH5, BRCA2) were then 
analyzed for pleiotropic association with cancer risk (Table 2). RAD51B-associated marker, 
rs11844632, had an overall (pleiotropic) OR of 0.90 (95% CI: 0.88–0.93; p = 5.46 × 10−12) 
across multiple cancer sites. The highly significant inverse association was limited to breast 
cancer (p = 8.14 × 10−9), ER-negative breast cancer (p = 0.01), overall prostate cancer (p = 
1.81 × 10−4), aggressive prostate cancer (2.46 × 10−3), and colon cancer (p = 0.01). 
Associations with lung cancer and ovarian cancer were in the opposite direction of effect 
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and not statistically significant. MSH5-associated marker, rs3115672, had an overall 
(pleiotropic) OR of 1.18 (95% CI: 1.12–1.24; p = 2.53 × 10−8). The marker had a highly 
significant association with lung cancer (p = 3.99 × 10−11), and had weaker associations 
with colon (p = 0.051), ovarian cancer (serous subtype) (p = 0.050), and lung 
(adenocarcinoma subtype) (p = 0.03) cancer. BRCA2-associated marker, rs56404467, was 
borderline significant, having an overall (pleiotropic) OR of 1.39 (95% CI: 1.21–1.61; p = 
5.70 × 10−6), driven by an association with overall lung cancer (p = 2.14 × 10−7), colon 
cancer (p = 7.33 × 10−3), and a weaker association with lung adenocarcinoma (p = 0.01).
To examine whether genomic variations in DNA repair genes might have small, but 
consistent, effects across cancer sites, left undetected due to being sub-genome wide 
significant, Q-Q plots were generated using the SNP data from the DNA repair gene regions, 
for each cancer dataset (Figure 2). Breast, prostate, and lung (overall and the 
adenocarcinoma subtype) cancer each showed deviations in p-value distribution greater than 
would be expected by chance, suggesting small but consistent effects in DNA repair genes 
may exist. Analysis of the genomic inflation factor (λ) was also performed on each cancer 
site database (42). A standard allelic test for association was performed, based on the 
median of the χ2 distribution with d.f. = 1. The λ values produced a modest deviation from 
the expected value of 1, consistent with the Q-Q plots and also suggestive of an excess 
number of significant associations in some of the cancer sites. The λ values for each dataset 
are as follows: breast = 1.10, breast (ER-negative) = 0.96, colon = 0.98, lung = 1.02, lung 
(adenocarcinoma) = 1.04, ovarian = 1.02, ovarian (serous) = 1.09, ovarian (mucinous) = 
1.02, prostate = 1.17, and prostate (aggressive) = 1.08.
In order to statistically model the sub-genome-wide-significant trends between DNA repair 
pathways and association with cancer risk, dimensional reduction of the GAME-ON dataset 
was performed via pathway analysis. Site-specific cancer associations with DNA repair 
pathways were evaluated using hierarchical modeling (Table 3). The analysis included 9,806 
SNPs. Analysis of the homologous recombination (HR) DNA repair pathway revealed 
pleiotropic associations with colon cancer (p = 4.18 × 10−4) and ovarian cancer: overall (p = 
1.39 × 10−6), the serous subtype (p = 1.65 × 10−6), and the mucinous subtype (p = 5.00 × 
10−5). Mismatch repair (MMR) showed pleiotropic associations with prostate cancer: 
overall (p = 3.54 × 10−5) and the aggressive sub-type (p = 2.76 × 10−3) and lung cancer: 
overall (4.86 × 10−4) and the adenocarcinoma subtype (p = 8.76 × 10−5). The DNA repair 
pathway, nucleotide excision repair, also showed a strong association with breast cancer: 
overall (p = 7.54 × 10−5) and the ER-negative subtype (p = 1.42 ×10−3) and weaker 
associations with ovarian cancer (p = 8.69 × 10−3), overall lung cancer (p = 0.024) and colon 
cancer (p = 0.027). All other DNA repair pathways tested showed at least some weaker 
associations with one or more cancer subtypes (p < 0.05).
Hierarchical modeling’s identification of pleiotropic pathway effects in HR and MMR 
pathways is consistent with the results obtained from individual SNP testing. In particular, 
RAD51B and BRCA2 are members of the HR pathway and MSH5 is a member of the MMR 
pathway. In order to determine whether these three loci, or a small number of other highly 
significant individual loci, significantly influence the overall hierarchical modeling analysis, 
a sensitivity analysis was performed. In the first sensitivity analysis, the RAD51B, BRCA2, 
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and MSH5 gene data were removed from the dataset and hierarchical modeling was repeated 
(Supplementary Table 4). In the second sensitivity analysis, any genes containing SNPs that 
had associations with p < 1 × 10−4, were removed from the dataset. This resulted in the 
removal of 6 genes (RAD51B, MSH5, BRCA2, DCLRE1B, SMEK1, RAD52) from the dataset 
prior to the hierarchical modeling procedure (Supplementary Table 5). Neither analysis 
appeared to reveal a significant change to the overall results, suggesting that a small number 
of highly significant loci were not driving the hierarchical modeling results. This suggests 
that the hierarchical modeling results were most likely a result of a large number of small 
effect sizes throughout the dataset.
Discussion
DNA damage and repair are known to be critically important to carcinogenesis and rare 
mutations in critical DNA repair genes are known to be associated with unusually high 
cancer risk. However, previous GWAS of common genetic variants (MAF > 0.01) have only 
identified a handful of statistically significant loci known to function through their effects on 
DNA repair genes. It was hypothesized that this could be due to the inability of even large 
studies to detect weak effect sizes. This study tested this hypothesis through use of a large 
heterogeneous database and a flexible meta-analysis strategy, which represents an 
unprecedented increase in statistical power to detect associations among common variants of 
DNA repair genes. This analytical strategy was supplemented with a strategy of dimensional 
reduction of the dataset, through pathway analysis, to also detect evidence of trends of 
association between cancer risk and common variants that may escape common variant 
testing by not meeting the genome-wide significance testing criteria.
Our results indicated that the RAD51B locus was strongly associated with breast cancer and 
contained a weaker association with prostate cancer, although this did not achieve statistical 
significance. This locus has been previously associated with breast (43–45), prostate (18, 
46), and mucinous ovarian cancer risk (24). Of the associated SNPs at RAD51B, two were 
previously reported in the literature, rs10483813 and rs17828907 (18, 43–45, 47, 48). No 
associations were detected for mucinous ovarian cancer at this locus, but this may be due to 
the relatively small number of mucinous ovarian cancer cases included in this analysis (n = 
306).
From the MSH5 locus, although rs3131379 was previously found to be associated with lung 
cancer (27, 37, 49, 50), this SNP was not included in our analysis (because it was not present 
in all GAME-ON databases), and rs3115672 was identified as the most significant SNP at 
this locus instead. It should be noted that the pairwise LD between rs3131379 and 
rs3115672 is very high (R2 > 0.99). Our study strongly associated this locus with lung 
cancer, with only weaker, non-significant associations detected for colon cancer, lung 
adenocarcinoma and mucinous ovarian cancer. This gene has been previously associated 
with lung cancer (27, 37, 39, 50) and non-Hodgkin’s lymphoma risk (OR = 1.16, p = 0.03) 
(51). Interestingly, this locus has also been associated with individuals suffering from lupus 
erythematosus (52–54), who themselves are known to be predisposed to non-Hodgkin’s 
lymphoma and lung cancer, while have reduced rates of other solid cancers (55).
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Our results identified a SNP at genetic locus 13q13.1, near the BRCA2 gene. While 
mutations to BRCA2 have been known to be associated with multiple cancer types (10, 56, 
57), this SNP has not been previously identified as a common variant related to cancer 
susceptibility. The SNP showed strong association with lung cancer. The SNP was located 
within the analytical window of the BRCA2 gene (+/− 50 kB) but was within the FRY gene 
region, which is not a canonical DNA repair gene. Thus, this finding should be interpreted 
with more caution, as supportive evidence of the association of common variants of DNA 
repair with cancer. However, the possibility that this SNP could affect BRCA2 gene function 
cannot be ruled out. Furthermore, it represents a potentially novel finding that suggests need 
for further investigation. This SNP, rs56404467, is in a non-coding exon and likely does not 
affect the activity or function of the BRCA2 protein but may alter the rate of BRCA2 
translation. This contrasts to the smaller and non-functional BRCA2 protein resulting from a 
mutation and could explain the different pattern in cancer associations.
A previous analysis of the BRCA2 gene discovered a locus associated with squamous lung 
cancer, but this locus was not associated with lung adenocarcinoma, in contrast to our own 
findings (58). However, secondary analysis identified an additional genetic feature which 
may explain this discrepancy. There was a different, less significant loci, detected within the 
BRCA2 gene, but this did not meet the criteria for significance testing of p < 5.09 × 10−6 
(rs4942486, p = 0.003). We found that this less significant loci was not strongly associated 
with adenocarcinoma but was associated with overall lung cancer, as previously reported 
(58). Despite being within the same analytical window, the FRY and BRCA2 loci were over 
100,000 bases apart, located within different genes, and did not appear to be in high LD. 
Therefore, our results support the existence of two separate genetic association loci around 
the BRCA2 gene.
Overall, individual variant testing failed to find robust evidence for an association between 
common variants in DNA repair genes and cancer susceptibility. Few loci were identified 
and all genes had been previously associated with cancer susceptibility. Furthermore, 
evidence for pleiotropy among common variants in these genetic regions did not receive 
strong statistical support. However, analysis of Q-Q plots from specific cancer sites, using 
SNPs data from DNA repair gene regions, suggested that consistent association for common 
variants in DNA repair genes may exist but are likely difficult to detect due to their small 
effect sizes. In order to examine this possibility, pathway analysis was used as a tool to 
reduce the dimensionality of the dataset.
Hierarchical modeling provided statistical evidence that common variants of DNA repair 
genes are likely associated with cancer susceptibility. Homologous recombination, mismatch 
repair, and nucleotide excision repair showed strong statistical associations with cancer 
susceptibility, and for homologous recombination and mismatch repair, this association was 
present across multiple cancer sites. Sensitivity analysis suggested that these results were not 
due to the contribution of a few, highly significant loci, but through the combination of 
small, individual SNP effects throughout the entire dataset.
A limitation of our analyses is due to the availability of only aggregate summary-level data. 
Thus, we were unable to evaluate associations with non-aggressive prostate or ER-positive 
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breast cancers. Lack of individual level data also made it difficult to enforce a consistent 
definition of aggressive prostate cancer. Despite this, our findings support further 
exploration of associations with DNA repair genes in these subgroups.
The results from pathway analysis and individual loci testing clarify the scientific model of 
the association of common variants in DNA repair genes with cancer risk. Although rare 
variants in these genes are known to be strongly linked to cancer incidence, very few 
individual loci were detected in our analysis, even when using a large database and a 
powerful analytical approach. Robust statistical significance was only detected under 
pathway analysis, and was observed to be likely due to the contribution of small effect sizes 
from multiple genes in DNA repair pathway. These data suggest that common variants of 
DNA repair genes are associated with cancer risk, but that the associations tend to be weak. 
These results and their interpretation seem particularly plausible, given the epidemiological 
observation that mutations at some DNA repair genes have profound deleterious effects 
(Fanconi anemia, xeroderma pigmentosa, ataxia telangiectasia, etc.). Thus, there is a strong 
theoretical justification for why common variant effects on cancer predisposition in these 
genes may be difficult to detect, as they likely face strong, negative selection pressure. This 
observation provides further rationale for conducting future targeted sequencing to explore 
the role that rare variants play in determining cancer risk.
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Figure 1. 
Manhattan plot, illustrating p-values from 60,297 SNP associations generated from 1-sided 
ASSET meta-analysis. Statistical significance threshold is denoted by the red line (p = 5.09 
× 10−6).
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Figure 2. 
Observed versus expected p-values of DNA repair gene SNPs, by cancer site and overall 
meta-analysis. SNPs plotted were filtered using the SNAP online tool (see Methods and 
Materials) and were eliminated from the analysis if R2 > 0.70. Black dots = p-values from 
indicated dataset, green lines = 95% pointwise expected interval under the null hypothesis, 
red line = expected observations under the null hypothesis.
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Table 1
Summary of GAME-ON GWAS included in the ASSET Meta-Analysis1
Cancer Site Number of GWAS Cases (N) Controls (N)
CORECT: Colorectal 6 5,100 4,831
DRIVE: Breast 11 15,748 18,084
 ER-Negative 8 4,939 13,128
ELLIPSE: Prostate 6 14,160 12,724
 Aggressive 6 4,450 12,724
FOCI: Ovary 3 4,369 9,123
 Invasive Serous 3 2,556 9,123
 Invasive Mucinous 3 306 9,123
TRICL: Lung 6 12,160 16,838
 Adenocarcinoma 6 3,718 15,871
Abbreviations: N, number.
1All cancer cases for a particular site were included in meta-analyses, except where subsets were included or used in place of all cancer cases.
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Table 2
Summary statistics of top genetic variants at the RAD51B (14q24.1), MSH5 (6p21.33), and BRCA2 (13q13.1) 
loci.
rs11844632 (14q24.1) OR (95% CI) p-value
1-sided ASSET Analysis 0.90 (0.88–0.93) 5.46×10−12
Breast (Overall) 0.90 (0.86–0.93) 8.14×10−9
Prostate (Overall) 0.91 (0.87–0.95) 2.74×10−6
Prostate (Aggressive) 0.92 (0.86–0.97) 2.46×10−3
Bresat (ER Neg) 0.93 (0.87–0.98) 0.01
Colon (Overall) 0.92 (0.86–0.98) 0.01
Ovarian (Overall) 1.06 (0.99–1.12) 0.08
Ovarian (Mucinous) 1.04 (0.97–1.12) 0.26
Ovarian (Serous) 1.09 (0.92–1.28) 0.31
Lung (Overall) 0.99 (0.95–1.03) 0.52
Lung (Adenocarcinoma) 1.00 (0.94–1.06) 0.91
rs3115672 (6p21.33) OR (95% CI) p-value
1-sided ASSET Analysis 1.18 (1.12–1.25) 2.53×10−8
Lung (Overall) 1.20 (1.14–1.27) 3.99×10−11
Lung (Adenocarcinoma) 1.11 (1.01–1.21) 0.03
Ovarian (Serous) 1.11 (1.00–1.23) 0.05
Colon (Overall) 1.10 (1.00–1.21) 0.05
Ovarian (Overall) 1.06 (0.98–1.15) 0.18
Prostate (Overall) 0.96 (0.91–1.02) 0.21
Breast (ER Neg) 1.05 (0.96–1.15) 0.28
Ovarian (Mucinous) 1.09 (0.86–1.37) 0.48
Prostate (Aggressive) 0.98 (0.89–1.07) 0.59
Breast (Overall) 1.01 (0.95–1.06) 0.82
rs56404467 (13q13.1) OR (95% CI) p-value
1-sided ASSET Analysis 1.39 (1.21–1.61) 5.70×10−6
Lung (Overall) 1.43 (1.25–1.64) 2.14×10−7
Colon (Overall) 1.31 (1.08–1.60) 7.33×10−3
Lung (Adenocarcinoma) 1.32 (1.06–1.64) 0.01
Breast (Overall) 1.10 (0.95–1.27) 0.19
Breast (ER Neg) 1.16 (0.88–1.54) 0.30
Prostate (Aggressive) 1.15 (0.88–1.50) 0.32
Ovarian (Serous) 1.12 (0.89–1.41) 0.32
Ovarian (Mucinous) 0.85 (0.46–1.56) 0.60
Prostate (Overall) 1.03 (0.87–1.22) 0.71
Ovarian (Overall) 1.03 (0.85–1.24) 0.78
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2016 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Scarbrough et al. Page 18
Ta
bl
e 
3
St
at
ist
ic
al
 a
ss
oc
ia
tio
ns
 (p
-va
lue
s) 
for
 ca
nc
er 
ris
k v
ers
us
 ge
ne
tic
 va
ria
tio
n w
ith
in 
DN
A 
rep
air
 pa
thw
ay
.1
Si
ng
le
 S
tr
an
d 
Br
ea
k 
R
ep
ai
r
D
ou
bl
e 
St
ra
nd
 B
re
ak
 R
ep
ai
r
O
th
er
Ba
se
 E
xc
isi
on
R
ep
ai
r
N
uc
le
ot
id
e
Ex
ci
sio
n 
R
ep
ai
r
M
ism
at
ch
R
ep
ai
r
Tr
an
sle
sio
n
Sy
nt
he
sis
Fa
nc
on
i A
ne
m
ia
H
om
ol
og
ou
s
R
ec
om
bi
na
tio
n
N
on
-h
om
ol
og
ou
s
en
d 
joi
nin
g
C
he
ck
 P
oi
nt
Fa
ct
or
s
C
an
ce
r (
Su
bt
yp
e)
 
Co
lo
n 
(O
ve
ral
l)
0.
01
6
0.
02
7
0.
61
4
0.
34
2
0.
96
9
4.
18
E-
04
0.
35
4
0.
54
6
 
B
re
as
t (
Ov
era
ll)
0.
25
7
7.
98
E-
05
0.
72
6
0.
43
1
0.
01
7
0.
91
4
0.
11
7
0.
49
6
 
B
re
as
t (
ER
 N
eg
ati
ve
)
0.
58
7
1.
42
E-
03
0.
03
2
0.
88
9
0.
26
1
0.
54
2
3.
13
E-
03
0.
19
3
 
Pr
os
ta
te
 (O
ve
ral
l)
0.
40
1
0.
10
9
3.
57
E-
05
0.
05
6
0.
23
2
0.
24
1
0.
05
7
0.
21
7
 
Pr
os
ta
te
 (A
gg
res
siv
e)
0.
32
7
0.
65
8
2.
76
E-
03
0.
45
5
0.
10
2
0.
41
6
5.
04
E-
06
0.
55
5
 
O
va
ria
n 
(O
ve
ral
l)
3.
19
E-
03
8.
69
E-
03
0.
55
2
0.
50
0
0.
58
6
1.
39
E-
06
0.
27
6
0.
16
9
 
O
va
ria
n 
(S
ero
us
)
0.
01
5
0.
90
5
0.
78
8
0.
77
2
0.
85
7
1.
65
E-
06
0.
86
1
0.
76
9
 
O
va
ria
n 
(M
uc
ino
us
)
0.
08
2
0.
07
6
0.
55
0
0.
05
9
2.
40
E-
04
5.
00
E-
05
1.
48
E-
04
3.
27
E-
04
 
Lu
ng
 (O
ve
ral
l)
1.
03
E-
03
0.
02
4
4.
63
E-
04
0.
88
5
0.
43
5
0.
75
9
0.
18
1
0.
19
3
 
Lu
ng
 (A
de
no
ca
rci
no
ma
)
0.
53
13
0.
80
4
8.
50
E-
05
0.
02
0
0.
72
1
0.
26
8
2.
64
E-
03
0.
60
2
C
ou
nt
s b
y 
D
N
A
 R
ep
ai
r P
at
hw
ay
 
A
ll 
SN
Ps
87
58
10
67
6
70
80
30
16
77
25
13
51
6
40
54
51
94
 
SN
A
P 
Fi
lte
re
d 
SN
Ps
15
68
18
50
11
74
43
9
11
91
20
47
55
7
88
0
 
G
en
es
37
47
25
13
30
44
15
22
1 B
ol
de
d 
p-
va
lu
es
 <
 0
.0
5 
in
di
ca
te
 cr
ite
ria
 fo
r s
ig
ni
fic
an
ce
.
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2016 July 01.
